| Cash Flow | 2025-06-30 |
|---|---|
| Forgiveness of unrelated vendor payables | -2,142,297 |
| Change in fair value of deferred underwriting fee - common stock payable | 756,000 |
| Change in the fair value of warrant liabilities | 116,894 |
| Net income (loss) | -214,239 |
| Depreciation | 743 |
| Due from related party, current | -3,427,000 |
| Prepaid and other current assets | 43,442 |
| Accounts payable and accrued expenses | -2,043,405 |
| Accrued interest, related parties | 177,800 |
| Accrued maintenance fee | -360,000 |
| Due to research and development partner | -1,782,297 |
| Due to related party | -101,500 |
| Net cash used in operating activities | -8,975,859 |
| Loans to iris acquisition corp | -775,000 |
| Net cash used in investing activities | -775,000 |
| Gross proceeds from issuance of common stock for pipe investment | 10,556,500 |
| Payment of transaction costs | -2,563,738 |
| Proceeds from issuance of short-term debt, related party | 4,340,000 |
| Repayment of short-term debt, related party | -1,300,000 |
| Net cash provided by financing activities | 11,032,762 |
| Net change in cash | 1,281,903 |
| Cash and cash equivalents at beginning of period | 56,319 |
| Cash and cash equivalents at end of period | 1,338,222 |
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)